Skip to main content

Outcomes for Nitazoxanide Treatment in a Case Series of Patients with Primary Immunodeficiencies and Rubella Virus-Associated Granuloma

Abstract

Purpose

Nitazoxanide was recently reported as having in vitro effectiveness against the rubella virus. Immunodeficiency-related vaccine-derived rubella occurs in some patients who have an inherited immunodeficiency and who received the MMR vaccine. This study investigated the in vivo effectiveness of nitazoxanide therapy.

Methods

This is a retrospective analysis of seven patients treated with nitazoxanide as salvage therapy for immunodeficiency-related vaccine-derived rubella infection. The patients were recruited from an ongoing rubella detection surveillance project.

Results

Seven patients with persistent rubella were treated with nitazoxanide and one demonstrated significant clinical improvement. Two additional patients exhibited diminished viral capsid production with one patient having transient slowing of progression. The cohort overall generally had low T cell counts and had a high burden of comorbidities. There were three deaths. Two deaths were from PML and one was related to hematopoietic stem cell transplantation.

Conclusions

Nitazoxanide has limited in vivo anti-viral effects for immunodeficiency-related vaccine-derived rubella. Most patients did not exhibit clinical improvement.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. Tondury G, Smith DW. Fetal rubella pathology. J Pediatr. 1966;68:867–79.

    Article  CAS  PubMed  Google Scholar 

  2. Fraser JR, Cunningham AL, Hayes K, Leach R, Lunt R. Rubella arthritis in adults. Isolation of virus, cytology and other aspects of the synovial reaction. Clin Exp Rheumatol. 1983;1:287–93.

    CAS  PubMed  Google Scholar 

  3. Ferrini W, Aubert V, Balmer A, Munier FL, Abouzeid H. Anterior uveitis and cataract after rubella vaccination: a case report of a 12-month-old girl. Pediatrics. 2013;132:e1035–8.

    Article  PubMed  Google Scholar 

  4. Abernathy E, Peairs RR, Chen MH, Icenogle J, Namdari H. Genomic characterization of a persistent rubella virus from a case of Fuch’ uveitis syndrome in a 73 year old man. J Clin Virol. 2015;69:104–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Bodemer C, Sauvage V, Mahlaoui N, Cheval J, Couderc T, Leclerc-Mercier S, et al. Live rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous granulomas in patients with primary immunodeficiency. Clin Microbiol Infect. 2014;20:O656–63.

    Article  CAS  PubMed  Google Scholar 

  6. Perelygina L, Plotkin S, Russo P, Hautala T, Bonilla F, Ochs HD, et al. Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies. J Allergy Clin Immunol. 2016;138:1436–1439 e11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Privette ED, Ram G, Treat JR, Yan AC, Heimall JR. Healing of granulomatous skin changes in ataxia-telangiectasia after treatment with intravenous immunoglobulin and topical mometasone 0.1% ointment. Pediatr Dermatol. 2014;31:703–7.

    Article  PubMed  Google Scholar 

  8. Dudgeon JA, Marshall WC, Peckham CS. Humoral immune responses in congenital rubella. Lancet. 1972;2:480–1.

    Article  CAS  PubMed  Google Scholar 

  9. Perelygina L, Hautala T, Seppanen M, Adebayo A, Sullivan KE, Icenogle J. Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency. Antivir Res. 2017;147:58–66.

    Article  CAS  PubMed  Google Scholar 

  10. Speckmann C, Doerken S, Aiuti A, Albert MH, Al-Herz W, Allende LM, et al. A prospective study on the natural history of patients with profound combined immunodeficiency: an interim analysis. J Allergy Clin Immunol. 2017;139:1302–1310 e4.

    Article  PubMed  Google Scholar 

Download references

Funding

This study was supported by the Wallace Chair of Pediatrics and the CDC.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kathleen E. Sullivan.

Ethics declarations

Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, US Department of Health and Human Services.

Conflict of Interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Perelygina, L., Buchbinder, D., Dorsey, M.J. et al. Outcomes for Nitazoxanide Treatment in a Case Series of Patients with Primary Immunodeficiencies and Rubella Virus-Associated Granuloma. J Clin Immunol 39, 112–117 (2019). https://doi.org/10.1007/s10875-019-0589-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-019-0589-0

Keywords

  • Granulomas
  • chronic inflammation
  • vaccine
  • nitazoxanide
  • MMR